Clinical Data, Inc.
One Gateway Center
Suite 702
Newton,
MA 02458
United States - Map
Phone: 617-527-9933
Fax: 617-965-0445
Web Site: http://www.clda.com
| Clinical Data, Inc. operates as a global biotechnology company developing early and late stage targeted therapeutics, as well as genetic and pharmacogenomic tests that detect serious diseases and help predict drug safety, tolerability, and efficacy. Its late-stage compounds include Vilazodone, a potential drug candidate for the treatment of depression, and Stedivaze, a potential cardiac stress agent. The company employs biomarker strategies and technologies to develop targeted therapeutics with advantages over existing treatments to help patients, healthcare professionals, and payers. Its PGxHealth division is leveraging its biomarker discovery expertise and intellectual property to develop and commercialize pharmacogenomic tests to detect serious diseases and help predict drug safety, tolerability, and efficacy. PGxHealth built the commercial, managed care, and CLIA-certified laboratory infrastructure and capabilities to support its marketed tests, including the FAMILION family of genetic tests for inherited heart diseases and PGxPredict tests for predicting drug response. The company has a collaboration and licensing agreement with CombinatoRx Inc. to develop an adenosine A2A agonist compound in a combination therapy for the treatment of multiple myeloma and other B-cell cancers. The company was founded in 1969 and is headquartered in Newton, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Andrew J. Fromkin , 42
Chief Exec. Officer, Pres and Exec. Director |
N/A
| N/A | Mr. C. Evan Ballantyne , 49
Chief Financial Officer and Exec. VP |
N/A
| N/A | Mr. Caesar J. Belbel , 49
Chief Legal Officer and Exec. VP |
N/A
| N/A | Dr. Carol R. Reed M.D., 56
Chief Medical Officer and Exec. VP |
N/A
| N/A | Mr. John A. Schultz , 47
Sr. VP of Licensing & Strategic Devel. (PGxHealth) |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
Profile
